Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability

Mol Cancer Ther (2024) 23 (11): 1530–1543.

https://doi.org/10.1158/1535-7163.MCT-23-0591

Published: 04 November 2024

View articletitled, Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability

Includes: Supplementary data

Journal Articles

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher Espelin, Neeraj Kohli, Bahar Matin, Yulius Setiady, Michael L. Miller, Thomas A. Keating, Ravi Chari, Jan Pinkas, Richard Gregory, Greg M. Thurber

Mol Cancer Ther (2021) 20 (1): 203–212.

https://doi.org/10.1158/1535-7163.MCT-20-0451

Published: 05 January 2021

View articletitled, Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Includes: Supplementary data

Journal Articles

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

Jeffrey D. Kearns, Raghida Bukhalid, Mark Sevecka, Gege Tan, Nastaran Gerami-Moayed, Shannon L. Werner, Neeraj Kohli, Olga Burenkova, Callum M. Sloss, Anne M. King, Jonathan B. Fitzgerald, Ulrik B. Nielsen, Beni B. Wolf

Mol Cancer Ther (2015) 14 (7): 1625–1636.

https://doi.org/10.1158/1535-7163.MCT-14-0772

Published: 06 July 2015

View articletitled, Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

Includes: Supplementary data

Journal Articles

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. Olivier, Jr, Birgit Schoeberl, Ulrik B. Nielsen, Alexey A. Lugovskoy

Mol Cancer Ther (2014) 13 (2): 410–425.

https://doi.org/10.1158/1535-7163.MCT-13-0255

Published: 09 February 2014

View articletitled, MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Includes: Supplementary data

Journal Articles

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms, Sharlene Adams, Violette Paragas, Shinji Oyama, Bo Zhang, Lia Luus, Ryan Overland, Stephanie Nguyen, Jinming Gu, Neeraj Kohli, Matt Wallace, Michael J. Feldhaus, Arthur J. Kudla, Birgit Schoeberl, Ulrik B. Nielsen

Mol Cancer Ther (2012) 11 (3): 582–593.

https://doi.org/10.1158/1535-7163.MCT-11-0820

Published: 06 March 2012

View articletitled, Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Includes: Supplementary data

Journal Articles

Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.

Alexey Lugovskoy, Bryan Johnson, Jason Baum, Sharlene Adams, Jian Tang, Neeraj Kohli, Rachel Rennard, Lihui Xu, Yang Jiao, Ulrik Nilesen, Jonathan Fitzgerald

Mol Cancer Ther (2011) 10 (11_Supplement): B205.

https://doi.org/10.1158/1535-7163.TARG-11-B205

Published: 12 November 2011

View articletitled, Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.

Journal Articles

Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.

Gege Tan, Jeffrey D. Kearns, Nastaran Gerami-Moayed, Neeraj Kohli, Shannon L. Werner, Anne M. King, Callum M. Sloss, Raghida Bukhalid, Ulrik B. Nielsen

Mol Cancer Ther (2011) 10 (11_Supplement): A210.

https://doi.org/10.1158/1535-7163.TARG-11-A210

Published: 12 November 2011

View articletitled, Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.

Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.

Email alerts

AACR Journals

Update search

Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.

Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only